主动脉瘤形成过程中白细胞介素-1通路的内皮向间质转化
该研究在小鼠主动脉瘤模型中探讨内皮向间质转化(EndMT)及白细胞介素-1(IL-1)信号的作用。结果显示弹性蛋白酶处理诱导主动脉扩张并上调EndMT转录因子和间质标志物、下调内皮标志物;IL-1受体1基因敲除或Anakinra药物抑制均减轻主动脉扩张及上述分子改变。结论认为EndMT存在于主动脉瘤病中,IL-1信号缺失可减弱该过程,EndMT可能是未来治疗潜在靶点。
要点
- 弹性蛋白酶处理导致小鼠主动脉扩张并诱导EndMT转录因子及间质标志物表达、内皮标志物丢失。
- 内皮特异性IL-1受体1敲除或Anakinra治疗均减轻弹性蛋白酶诱导的主动脉扩张及EndMT分子改变。
- EndMT是理解主动脉瘤病的新通路,可能成为未来治疗潜在靶点。
核心结论
- EndMT存在于主动脉瘤病中,IL-1信号缺失可减弱该过程。
- EndMT代表理解主动脉瘤病的新通路,可能成为未来治疗潜在靶点。
研究设计与样本
- 使用新型CDH5-Cre谱系追踪小鼠,通过外膜周弹性蛋白酶处理完整主动脉建立小鼠主动脉瘤模型。
- 通过免疫组化和免疫荧光分析EndMT转录因子及内皮和间质细胞标志物(每组n=10)。
- 为确定IL-1信号作用,对内皮特异性IL-1受体1敲除和野生型小鼠(每组n=10)给予弹性蛋白酶处理。
- 此外,C57/BL6小鼠接受IL-1受体1拮抗剂Anakinra(n=7)或载体(n=8)治疗。
主要发现
- 弹性蛋白酶处理组主动脉扩张大于对照组(弹性蛋白酶组97.0%±34.0% vs 对照组5.3%±4.8%,P<.001)。
- IL-1受体1基因敲除减轻主动脉扩张(对照组126.7%±38.7% vs IL-1受体1敲除组35.2%±14.7%,P<.001)。
- Anakinra药物抑制IL-1受体1也减轻主动脉扩张(载体组146.3%±30.1% vs Anakinra组63.5%±23.3%,P<.001)。
- 弹性蛋白酶处理上调EndMT转录因子(Snail、Slug、Twist、ZNF)和间质细胞标志物(S100、α平滑肌肌动蛋白),并导致内皮细胞标志物(血管内皮钙黏蛋白、内皮型一氧化氮合酶、血管性血友病因子)丢失。
- IL-1受体1敲除和Anakinra治疗减弱了上述改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endothelial to mesenchymal transition may represent a key link between inflammatory stress and endothelial dysfunction seen in aortic aneurysm disease. Endothelial to mesenchymal transition is regulated by interleukin-1β, and previous work has demonstrated an essential role of interleukin-1 signaling in experimental aortic aneurysm models. We hypothesize that endothelial to mesenchymal transition is present in murine aortic aneurysms, and loss of interleukin-1 signaling attenuates this process. METHODS: Murine aortic aneurysms were created in novel CDH5-Cre lineage tracking mice by treating the intact aorta with peri-adventitial elastase. Endothelial to mesenchymal transition transcription factors as well as endothelial and mesenchymal cell markers were analyzed via immunohistochemistry and immunofluorescence (n = 10/group). To determine the role of interleukin-1 signaling, endothelial-specific interleukin-1 receptor 1 knockout and wild-type mice (n = 10/group) were treated with elastase. Additionally, C57/BL6 mice were treated with the interleukin-1 receptor 1 antagonist Anakinra (n = 7) or vehicle (n = 8). RESULTS: Elastase treatment yielded greater aortic dilation compared with controls (elastase 97.0% ± 34.0%; control 5.3% ± 4.8%; P < .001). Genetic deletion of interleukin-1 receptor 1 attenuated aortic dilation (control 126.7% ± 38.7%; interleukin-1 receptor 1 knockout 35.2% ± 14.7%; P < .001), as did pharmacologic inhibition of interleukin-1 receptor 1 with Anakinra (vehicle 146.3% ± 30.1%; Anakinra 63.5% ± 23.3%; P < .001). Elastase treatment resulted in upregulation of endothelial to mesenchymal transition transcription factors (Snail, Slug, Twist, ZNF) and mesenchymal cell markers (S100, alpha smooth muscle actin) and loss of endothelial cell markers (vascular endothelial cadherin, endothelial nitric oxide synthase, von Willebrand factor). These changes were attenuated by interleukin-1 receptor 1 knockout and Anakinra treatment. CONCLUSIONS: Endothelial to mesenchymal transition occurs in aortic aneurysm disease and is attenuated by loss of interleukin-1 signaling. Endothelial dysfunction through endothelial to mesenchymal transition represents a new and novel pathway in understanding aortic aneurysm disease and may be a potential target for future treatment.
引用
- Millar JK, Salmon M, Nasser E, et al. Endothelial to mesenchymal transition in the interleukin-1 pathway during aortic aneurysm formation. J Thorac Cardiovasc Surg. 2023. PMID: 37951532. doi:10.1016/j.jtcvs.2023.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。